Recent Updates
Recently added Catalysts
IRWD Neutral Sentiment

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Key Takeaway: Ironwood Pharmaceuticals has reported its financial results for the first quarter of 2024. The report includes various aspects of the company's performance and operations. However, specific details regarding revenue, expenses, or strategic initiatives were not highlighted in the provided text.
Price reaction · baseline $8.12 (2024-05-08 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
-17%
day 1
-13.8%
day 3 · peak
-18.3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)

Full Press Release Details

• Company Company Overview Leadership Open Payments & Transparency
• Science & Medicine Therapeutic Focus Pipeline Product
• Patients Overview
• Responsibility Overview Diversity, Equity & Inclusion Sustainability Safety & Compliance Patients & Research Community Giving
• Careers Working at Ironwood Internships, Co-ops and Fellowships Open Positions
• Investors & Media Contact Us
• Company Overview
• Leadership
• Open Payments & Transparency
• Therapeutic Focus
• Pipeline
• Product
• Overview
• Overview
• Diversity, Equity & Inclusion
• Sustainability
• Safety & Compliance
• Patients & Research
• Community Giving
• Working at Ironwood
• Internships, Co-ops and Fellowships
• Open Positions
• Investors & Media
• Contact Us
Last updated: May 9, 2024